A Phase 3 interventional study of Saxagliptin 5 mg and Placebo 5 mg for Saxagliptin in Type 2 Diabetes Mellitus, sponsored by AstraZeneca. Completed at 17 sites in China. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2018-02-05.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 74 studies testing saxagliptin in Diabetes Mellitus, Type 2 — 1 open to participants now, 1 under way, none of them phase 3. saxagliptin · Diabetes Mellitus, Type 2.
Among the 74 studies testing saxagliptin in Diabetes Mellitus, Type 2, this one is the 5th largest by enrollment, is one of 10 that started in 2014, is one of 27 in phase 3, and was the 54th registered.
10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →1 of the 74 studies testing saxagliptin in Diabetes Mellitus, Type 2 is open now, in 1 country. Recruiting first, the newest first:
The University of Texas Health Science Center at San Antonio · Sites in United States
Ages 18–65 · Healthy volunteers
By country, each count listing its studies:
saxagliptin: first FDA approval 2009 (ONGLYZA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 18 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
74 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 4 · Phase 3 28 · Phase 4 25
First in 2003; this study’s year is marked. 10 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,136 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 138 across the 74 interventional studies. Of the 64 that completed or were terminated, 47 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
52 of 74 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,505 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
345 studies in Diabetes Mellitus, Type 2 by AstraZeneca: 13 open now, 15 under way, 9 of them phase 3. Of 325 finished, 149 (46%) have results posted.
Among the 345 studies in Diabetes Mellitus, Type 2 by AstraZeneca, this one is the 21st largest by enrollment of the 280 interventional ones that give a count, is one of 17 that started in 2014, is one of 119 in phase 3, and was the 239th registered.
AstraZeneca’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
1 of the studies testing saxagliptin in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02969798The University of Texas Health Science Center at San AntonioPre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT) | 2027-02-28 |
Add it to your calendar (.ics) → With an account.
Among the 74 studies testing saxagliptin in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 345 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
A Multicenter, Randomized, Double-Blind, Active-Controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Saxagliptin in Combination with Metformin IR as Initial Therapy Compared to Saxagliptin Monotherapy and to Metformin IR Monotherapy in Subjects with Type 2 Diabetes who have Inadequate Glycaemic Control
Allocation: Randomized Endpoint Classification: Efficacy/Safety study Intervention Model: Parallel Assignment Masking: Double Blind Primary Purpose: Treatment
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Saxagliptin 5 mg once daily and metformin 500 mg once daily, then titrate. Acarbose will be used as rescue medication as needed.
Drug: Saxagliptin 5 mg · Drug: Metformin 500 mg with titration
Saxagliptin 5 mg once daily and Placebo 500 mg once daily, then titrate. Acarbose will be used as rescue medication as needed.
Drug: Saxagliptin 5 mg · Drug: Placebo 500 mg for metformin (with titration)
Placebo 5 mg once daily and metformin 500 mg once daily, then titrate. Acarbose will be used as rescue medication as needed.
Drug: Placebo 5 mg for Saxagliptin · Drug: Metformin 500 mg with titration
Tablet, Oral, 5 mg, Once daily in the morning
Also known as: Onglyza, BMS-477118
Tablet, Oral, 5 mg, Once daily in the morning
Tablet, 500 mg, Once daily in the evening the first two weeks and thereafter according to titration.
Drug page: Metformin
Tablet, 500 mg, Once daily in the evening the first two weeks and thereafter according to titration.
Also known as: Glucophage
Change From Baseline in HbA1c From Baseline to Week 24 Provided That it is Prior to Rescue
To evaluate the efficacy of the combination therapy (saxagliptin + metformin) when compared to placebo + metformin and placebo + saxagliptin with respect to reduction in HbA1c (%) at the end of 24 weeks of double-blinded treatment.
Time frame: Baseline to Week 24 (prior to rescue)
Glycemic Response Defined as HbA1c < 7.0% at Week 24
To evaluate the efficacy of the combination therapy (saxagliptin + metformin) when compared to placebo + metformin and placebo + saxagliptin with respect to the proportion of subjects achieving a therapeutic glycemic response defined as HbA1c \< 7.0% at the end of 24 weeks of double-blinded treatment.
Time frame: Week 24 (prior to rescue)
Change From Baseline to Week 24 (Prior to Rescue) in Fasting Plasma Glucose
To evaluate the efficacy of the combination therapy (saxagliptin + metformin) when compared to placebo + metformin and placebo + saxagliptin with respect to reduction in fasting plasma glucose at the end of 24 weeks of double-blinded treatment.
Time frame: Baseline to Week 24 prior to rescue
Change From Baseline to Week 24 (Prior to Rescue) in Area Under the Curve From 0-180 Minutes for Postprandial Glucose Response to a Meal Tolerance Test
To evaluate the efficacy of the combination therapy (saxagliptin + metformin) when compared to placebo + metformin and placebo + saxagliptin with respect to change in 180-minute postprandial glucose response to a meal tolerance test at the end of 24 weeks of double-blinded treatment.
Time frame: Baseline to Week 24 prior to rescue
Glycemic Response Defined as HbA1c ≤ 6.5% at Week 24
To evaluate the efficacy of the combination therapy (saxagliptin + metformin) when compared to placebo + metformin and placebo + saxagliptin with respect to the proportion of subjects achieving a therapeutic glycemic response defined as HbA1c ≤ 6.5% at the end of 24 weeks of double-blinded treatment.
Time frame: Week 24 (prior to rescue)
Change From Baseline to Week 24 in 120-minute Postprandial Glucose Response to a Meal Tolerance Test
To evaluate the efficacy of the combination therapy (saxagliptin + metformin) when compared to placebo + metformin and placebo + saxagliptin with respect to change in 120-minute postprandial glucose response to a meal tolerance test at the end of 24 weeks of double-blinded treatment.
Time frame: Baseline to Week 24 prior to rescue
Patients Rescued for Failing to Achieve Pre-specified Glycemic Targets or Discontinuation for Lack of Efficacy During the 24-week Double-blind Treatment Phase
To evaluate the efficacy of the combination therapy (saxagliptin + metformin) when compared to placebo + metformin and placebo + saxagliptin with respect to the proportion of subjects requiring rescue for failing to achieve pre-specified glycemic targets or discontinuing for lack of efficacy within the 24 weeks of double-blinded treatment.
Time frame: Baseline to Week 24
The study was conducted in 25 centers between 18 December 2014 and 03 August 2016.
| Milestone | METFORMIN + PLACEBO 5MG QD | SAXAGLIPTIN 5MG QD + METFORMIN | SAXAGLIPTIN 5MG QD + PLACEBO |
|---|---|---|---|
| Started | 210 | 216 | 214 |
| Completed | 186 | 194 | 185 |
| Not completed | 24 | 22 | 29 |
| Withdrew: Adverse event | 4 | 3 | 3 |
| Withdrew: Death | 0 | 0 | 1 |
| Withdrew: Dev. of study spec. withdrawal criteria | 0 | 1 | 1 |
| Withdrew: Lack of efficacy | 0 | 1 | 1 |
| Withdrew: Withdrawal by subject | 17 | 14 | 16 |
| Withdrew: Lost to follow-up | 0 | 2 | 3 |
| Withdrew: Protocol violation | 3 | 1 | 4 |
To evaluate the efficacy of the combination therapy (saxagliptin + metformin) when compared to placebo + metformin and placebo + saxagliptin with respect to reduction in HbA1c (%) at the end of 24 weeks of double-blinded treatment.
| % HbA1c | Saxagliptin + Metformin | Saxagliptin + Placebo | Metformin + Placebo |
|---|---|---|---|
| Change From Baseline in HbA1c From Baseline to Week 24 Provided That it is Prior to Rescue | -3.007 ± 0.0706 | -2.123 ± 0.0701 | -2.794 ± 0.0715 |
To evaluate the efficacy of the combination therapy (saxagliptin + metformin) when compared to placebo + metformin and placebo + saxagliptin with respect to the proportion of subjects achieving a therapeutic glycemic response defined as HbA1c \< 7.0% at the end of 24 weeks of double-blinded treatment.
| Percentage of patients | Saxagliptin + Metformin | Saxagliptin + Placebo | Metformin + Placebo |
|---|---|---|---|
| Glycemic Response Defined as HbA1c < 7.0% at Week 24 | 81.8 | 44.3 | 71.1 |
To evaluate the efficacy of the combination therapy (saxagliptin + metformin) when compared to placebo + metformin and placebo + saxagliptin with respect to reduction in fasting plasma glucose at the end of 24 weeks of double-blinded treatment.
| mmol/L | Saxagliptin + Metformin | Saxagliptin + Placebo | Metformin + Placebo |
|---|---|---|---|
| Change From Baseline to Week 24 (Prior to Rescue) in Fasting Plasma Glucose | -3.25 ± 0.112 | -1.86 ± 0.111 | -2.94 ± 0.113 |
To evaluate the efficacy of the combination therapy (saxagliptin + metformin) when compared to placebo + metformin and placebo + saxagliptin with respect to change in 180-minute postprandial glucose response to a meal tolerance test at the end of 24 weeks of double-blinded treatment.
| mmol*min/L | Saxagliptin + Metformin | Saxagliptin + Placebo | Metformin + Placebo |
|---|---|---|---|
| Change From Baseline to Week 24 (Prior to Rescue) in Area Under the Curve From 0-180 Minutes for Postprandial Glucose Response to a Meal Tolerance Test | -1027.8 ± 36.22 | -611.9 ± 36.69 | -858.5 ± 37.36 |
To evaluate the efficacy of the combination therapy (saxagliptin + metformin) when compared to placebo + metformin and placebo + saxagliptin with respect to the proportion of subjects achieving a therapeutic glycemic response defined as HbA1c ≤ 6.5% at the end of 24 weeks of double-blinded treatment.
| Percentage of patients | Saxagliptin + Metformin | Saxagliptin + Placebo | Metformin + Placebo |
|---|---|---|---|
| Glycemic Response Defined as HbA1c ≤ 6.5% at Week 24 | 67.0 | 32.1 | 55.4 |
To evaluate the efficacy of the combination therapy (saxagliptin + metformin) when compared to placebo + metformin and placebo + saxagliptin with respect to change in 120-minute postprandial glucose response to a meal tolerance test at the end of 24 weeks of double-blinded treatment.
| mmol/L | Saxagliptin + Metformin | Saxagliptin + Placebo | Metformin + Placebo |
|---|---|---|---|
| Change From Baseline to Week 24 in 120-minute Postprandial Glucose Response to a Meal Tolerance Test | -7.09 ± 0.261 | -4.12 ± 0.262 | -5.95 ± 0.268 |
To evaluate the efficacy of the combination therapy (saxagliptin + metformin) when compared to placebo + metformin and placebo + saxagliptin with respect to the proportion of subjects requiring rescue for failing to achieve pre-specified glycemic targets or discontinuing for lack of efficacy within the 24 weeks of double-blinded treatment.
| Percentage of patients | Saxagliptin + Metformin | Saxagliptin + Placebo | Metformin + Placebo |
|---|---|---|---|
| Patients Rescued for Failing to Achieve Pre-specified Glycemic Targets or Discontinuation for Lack of Efficacy During the 24-week Double-blind Treatment Phase | 1.4 | 10.3 | 1.4 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| METFORMIN + PLACEBO 5MG QD | — | 11/210 (5.2%) | 30/210 (14.3%) |
| SAXAGLIPTIN 5MG QD + METFORMIN | — | 4/215 (1.9%) | 37/215 (17.2%) |
| SAXAGLIPTIN 5MG QD + PLACEBO | — | 12/214 (5.6%) | 21/214 (9.8%) |
| Event | METFORMIN + PLACEBO 5MG QD | SAXAGLIPTIN 5MG QD + METFORMIN | SAXAGLIPTIN 5MG QD + PLACEBO |
|---|---|---|---|
| Acute myocardial infarctionCardiac disorders | 1/210 | 0/215 | 0/214 |
| GastritisGastrointestinal disorders | 1/210 | 0/215 | 0/214 |
| Large intestine polypGastrointestinal disorders | 1/210 | 0/215 | 0/214 |
| Pancreatic massGastrointestinal disorders | 1/210 | 0/215 | 0/214 |
| Bile duct obstructionHepatobiliary disorders | 1/210 | 0/215 | 0/214 |
| CholecystitisHepatobiliary disorders | 1/210 | 0/215 | 0/214 |
| CholelithiasisHepatobiliary disorders | 1/210 | 0/215 | 0/214 |
| Localised infectionInfections and infestations | 1/210 | 0/215 | 0/214 |
| Plasma cell myelomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/210 | 0/215 | 0/214 |
| Cerebral infarctionNervous system disorders | 1/210 | 0/215 | 1/214 |
| Event | METFORMIN + PLACEBO 5MG QD | SAXAGLIPTIN 5MG QD + METFORMIN | SAXAGLIPTIN 5MG QD + PLACEBO |
|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 14/210 | 15/215 | 10/214 |
| DiarrhoeaGastrointestinal disorders | 13/210 | 14/215 | 6/214 |
| HyperlipidaemiaMetabolism and nutrition disorders | 7/210 | 11/215 | 6/214 |
| Age, Continuous(Years) | METFORMIN + PLACEBO 5MG QD | SAXAGLIPTIN 5MG QD + METFORMIN | SAXAGLIPTIN 5MG QD + PLACEBO | Total |
|---|---|---|---|---|
| Mean | 50.1 ± 11.08 | 50.4 ± 10.78 | 49.5 ± 10.93 | 50.0 ± 10.92 |
| Sex: Female, Male(Participants) | METFORMIN + PLACEBO 5MG QD | SAXAGLIPTIN 5MG QD + METFORMIN | SAXAGLIPTIN 5MG QD + PLACEBO | Total |
|---|---|---|---|---|
| Female | 76 | 76 | 62 | 214 |
| Male | 134 | 140 | 152 | 426 |
| Race/Ethnicity, Customized(Participants) | METFORMIN + PLACEBO 5MG QD | SAXAGLIPTIN 5MG QD + METFORMIN | SAXAGLIPTIN 5MG QD + PLACEBO | Total |
|---|---|---|---|---|
| Asian | 210 | 216 | 214 | 640 |
The record gives a start of Dec 2014, a primary completion of Aug 2016 and a completion of Aug 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2018, 1 year 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Saxagliptin · Metformin